Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

Summary Background This multicenter, open-label, phase Ib study was designed to assess the safety, pharmacokinetics and preliminary efficacy of ME-344, a mitochondrial inhibitor, administered in combination with the topoisomerase I inhibitor, topotecan, in patients with previously treated, locally a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2017-10, Vol.35 (5), p.627-633
Hauptverfasser:	Diamond, Jennifer R., Goff, Barbara, Forster, Martin D., Bendell, Johanna C., Britten, Carolyn D., Gordon, Michael S., Gabra, Hani, Waterhouse, David M., Poole, Mark, Ross Camidge, D., Hamilton, Erika, Moore, Kathleen M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anticancer properties Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cervical cancer Cervix Disease control DNA topoisomerase Dose-Response Relationship, Drug Drug Administration Schedule Fatigue Female Humans Inhibitors Isoflavones - administration & dosage Lung cancer Lung Neoplasms - drug therapy Lungs Male Medicine Medicine & Public Health Metastases Metastasis Middle Aged Mitochondria Mitochondria - drug effects Neoplasm Recurrence, Local - drug therapy Neutropenia Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Phase I Studies Quality Small cell lung carcinoma Studies Thrombocytopenia Topoisomerase I Inhibitors - administration & dosage Topotecan Topotecan - administration & dosage Toxic diseases Toxicity Uterine Cervical Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!